Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Nitroaniline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A known ✓ | Q13946 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Nitroaniline SCHEMBL5331149 | 1.00 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL29396517 | 0.98 | PDE7A (0.62) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL6000 | 0.98 | PDE7A (0.62) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL11093537 | 0.96 | PDE7A (0.56) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL20876419 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL28878330 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL5718349 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL859790 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL859788 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR | |
| 2-Nitroaniline SCHEMBL355101 | 0.95 | PDE7A (0.60) | PDE7ASMN1; SMN2TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114184562-A | Method for determining urokinase activity by chromogenic substrate method | 北京赛升药业股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-105696103-B | Carpet silk fire-retardant fiber of ultraviolet resistant nylon 6 of copoly type and preparation method thereof | 义乌市瑞宝智能科技有限公司 | 2017-10-31 | — | — | CN | claimed |
| CN-102619108-A | Protein reactive ultraviolet absorber and preparation method thereof | UNIV ZHEJIANG SCIENCE & TECH | 2012-08-01 | — | — | CN | claimed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-115926063-B | Self-healing PC material, and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118373770-A | Method for synthesizing 2-methyl-8-nitroquinoline | 百合花集团股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| CN-118240806-A | Liquid thrombin reagent | 仪器实验室公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4326723-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023219172-A1 | METHOD FOR PRODUCING PROCESSED VEGETABLE PROTEIN-CONTAINING COMPOSITION | 天野エンザイム株式会社 | 2023-11-16 | — | — | WO | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-0751134-B1 | Method of synthesizing 2-(2'-hydroxyphenyl) benzotriazole compounds | EASTMAN KODAK CO (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-5908625-A | ADMINISTERING A GENETIC ENGINEERED PROTEIN | BOEHRINGER MANNHEIM GMBH (DE) | 1999-06-01 | — | — | US | disclosed |
| US-5723122-A | FIBRINOLYTIC ACTIVITY | BOEHRINGER MANNHEIM GMBH (DE) | 1998-03-03 | — | — | US | disclosed |
| WO-1997049673-A1 | SELECTIVE THROMBIN INHIBITORS | LG CHEMICAL LTD. (KR) | 1997-12-31 | — | — | WO | disclosed |
| US-5670654-A | CYCLIZATION IN PRESENCE OF REDUCING AGENT | EASTMAN KODAK COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0751134-A1 | Method of synthesizing 2-(2'-hydroxyphenyl) benzotriazole compounds | EASTMAN KODAK COMPANY (US) | 1997-01-02 | — | — | EP | disclosed |
| EP-0074761-B1 | PEPTIDE-TYPE SUBSTRATES USEFUL IN THE QUANTITATIVE DETERMINATION OF ENDOTOXIN | WHITTAKER CORPORATION (US) | 1985-12-27 | — | — | EP | disclosed |
| US-4077971-A | ULTRAVIOLET ABSORBERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | PDE7A 1691/4885SMN1; SMN2 3303/4885TDP1 510/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | PDE7A 790/4885SMN1; SMN2 1644/4885TDP1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.